CCXI Summary

  1. NASDAQ
  2. >
  3. CCXI
TickerCCXI
DescriptionCHEMOCENTRYX INC
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Next Earnings DateAugust 9th, 2021
IV240.097123%
IV Percentile99th
IV Rank95.50%
IV Skew-35.127670
IV Skew Percentile7th
IV Skew SentimentBullish
Option Volume4,818
Price$13.51
Previous Close$13.53
52-Week High$70.29
52-Week Low$9.53
50-Day Moving Avg.$14.04
200-Day Moving Avg.$47.03
10-Day Avg. Volume4,872,080
20-Day Avg. Volume3,162,459
30-Day Avg. Volume3,190,840
3-Month Avg. Volume3,117,389
EPS-$0.92
Outstanding Shares69,749,569
Market Capitalization$923,484,300
CurrencyUSD
UpdatedJune 19th, 2021